SCHEMBL4021786

SCHEMBL4021786

Cc1cccc([C@@H]2[C@@H](C(=O)c3cccc(F)c3)CN(CCN3CCOCC3)C[C@H]2C(=O)c2cccc(F)c2)c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
TP53 P04637 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KDM4E B2RXH2 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
IDH1 O75874 1/20 0.40
GAA P10253 2/20 0.39
MAPT P10636 1/20 0.39
TDP2 O95551 1/20 0.39
CASP6 P55212 1/20 0.39
UBE2I P63279 1/20 0.39
HKDC1 Q2TB90 1/20 0.39
SAE1 Q9UBE0 1/20 0.39
UBA2 Q9UBT2 1/20 0.39
MTOR P42345 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4019805 0.97 ALDH1A1 (0.41) ALDH1A1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL4780063 0.89 ALDH1A1 (0.46) ALDH1A1RAB9ASMN1; SMN2KDM4EL3MBTL1
SCHEMBL4776822 0.89 ALDH1A1 (0.46) ALDH1A1RAB9ASMN1; SMN2KDM4EL3MBTL1
SCHEMBL4777781 0.89 ALDH1A1 (0.46) ALDH1A1RAB9ASMN1; SMN2KDM4EL3MBTL1
SCHEMBL4026452 0.88 ALDH1A1 (0.40) ALDH1A1MEN1KMT2AGAA
SCHEMBL4022116 0.87 CYP2C9 (0.41) ALDH1A1MEN1KMT2AGAAHPGD
SCHEMBL4028159 0.87 ALDH1A1 (0.39) ALDH1A1MEN1KMT2AGAA
SCHEMBL4019099 0.87 ALDH1A1 (0.35) ALDH1A1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL4894830 0.86 POLB (0.44) ALDH1A1SMN1; SMN2KDM4ETDP1L3MBTL1
SCHEMBL4795657 0.86 POLB (0.44) ALDH1A1SMN1; SMN2KDM4ETDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
EP-1962846-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-09-03 EP claimed
WO-2007059323-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-24 WO claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 ALDH1A1 258/4885NPC1 263/4885RAB9A 2228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.